Novartis AG (NYSE: NVS) Stock Competitors & Peer Comparison
See NVS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NVS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVS | $140.37 | -0.39% | 266.8B | 16.15 | $8.69 | +3.38% |
| LLY | $1,152.22 | -0.02% | 1.1T | 36.61 | $31.49 | +0.58% |
| JNJ | $269.99 | -0.09% | 650.6B | 25.16 | $10.73 | +1.94% |
| ABBV | $263.78 | -0.09% | 466.1B | 25.89 | $10.19 | +2.58% |
| MRK | $146.76 | -0.27% | 362.5B | 45.72 | $3.21 | +2.32% |
| AZN | $166.08 | -0.04% | 257.5B | 17.93 | $9.26 | +1.94% |
| AMGN | $385.65 | +2.47% | 205B | 16.98 | $22.37 | +2.58% |
| NVO | $43.24 | +0.12% | 192B | 10.76 | $4.02 | +4.13% |
| GILD | $150.11 | -0.52% | 186.4B | -384.90 | -$0.39 | +2.15% |
| PFE | $27.66 | +0.07% | 157.3B | 9.05 | $3.05 | +6.25% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
NVS vs LLY Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while LLY trades at $1,152.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas LLY's P/E ratio is 36.61. In terms of profitability, NVS's ROE is +0.30%, compared to LLY's ROE of +0.93%. Regarding short-term risk, NVS is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for NVS.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
NVS vs JNJ Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, JNJ has a market cap of 650.6B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while JNJ trades at $269.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas JNJ's P/E ratio is 25.16. In terms of profitability, NVS's ROE is +0.30%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, NVS is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for NVS.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
NVS vs ABBV Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, ABBV has a market cap of 466.1B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while ABBV trades at $263.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas ABBV's P/E ratio is 25.89. In terms of profitability, NVS's ROE is +0.30%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, NVS is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for NVS.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
NVS vs MRK Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, MRK has a market cap of 362.5B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while MRK trades at $146.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas MRK's P/E ratio is 45.72. In terms of profitability, NVS's ROE is +0.30%, compared to MRK's ROE of +0.07%. Regarding short-term risk, NVS is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for NVS.Check MRK's competition here
AstraZeneca PLC (NYSE: AZN)
NVS vs AZN Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, AZN has a market cap of 257.5B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while AZN trades at $166.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas AZN's P/E ratio is 17.93. In terms of profitability, NVS's ROE is +0.30%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVS is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
NVS vs AMGN Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, AMGN has a market cap of 205B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while AMGN trades at $385.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas AMGN's P/E ratio is 16.98. In terms of profitability, NVS's ROE is +0.30%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, NVS is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
NVS vs NVO Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, NVO has a market cap of 192B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while NVO trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas NVO's P/E ratio is 10.76. In terms of profitability, NVS's ROE is +0.30%, compared to NVO's ROE of +0.59%. Regarding short-term risk, NVS is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for NVS.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
NVS vs GILD Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, GILD has a market cap of 186.4B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while GILD trades at $150.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas GILD's P/E ratio is -384.90. In terms of profitability, NVS's ROE is +0.30%, compared to GILD's ROE of -0.16%. Regarding short-term risk, NVS is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
NVS vs PFE Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, PFE has a market cap of 157.3B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while PFE trades at $27.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas PFE's P/E ratio is 9.05. In terms of profitability, NVS's ROE is +0.30%, compared to PFE's ROE of +0.05%. Regarding short-term risk, NVS is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for NVS.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
NVS vs BMY Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, BMY has a market cap of 128.8B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while BMY trades at $63.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas BMY's P/E ratio is 10.63. In terms of profitability, NVS's ROE is +0.30%, compared to BMY's ROE of +0.47%. Regarding short-term risk, NVS is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BMY's competition here
Sanofi (NASDAQ: SNY)
NVS vs SNY Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, SNY has a market cap of 102B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while SNY trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas SNY's P/E ratio is 9.25. In terms of profitability, NVS's ROE is +0.30%, compared to SNY's ROE of +0.06%. Regarding short-term risk, NVS is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for NVS.Check SNY's competition here
GSK plc (NYSE: GSK)
NVS vs GSK Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, GSK has a market cap of 100.6B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while GSK trades at $50.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas GSK's P/E ratio is 10.85. In terms of profitability, NVS's ROE is +0.30%, compared to GSK's ROE of +0.24%. Regarding short-term risk, NVS is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
NVS vs BIIB Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, BIIB has a market cap of 31.8B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while BIIB trades at $215.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas BIIB's P/E ratio is 13.60. In terms of profitability, NVS's ROE is +0.30%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, NVS is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
NVS vs HZNP Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVS's ROE is +0.30%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVS is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for NVS.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
NVS vs GRFS Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while GRFS trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas GRFS's P/E ratio is 8.40. In terms of profitability, NVS's ROE is +0.30%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for NVS.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
NVS vs OGN Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while OGN trades at $13.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas OGN's P/E ratio is 4.09. In terms of profitability, NVS's ROE is +0.30%, compared to OGN's ROE of +0.23%. Regarding short-term risk, NVS is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for NVS.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
NVS vs AMRN Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, AMRN has a market cap of 286.9M. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while AMRN trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas AMRN's P/E ratio is -138.70. In terms of profitability, NVS's ROE is +0.30%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, NVS is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for NVS.Check AMRN's competition here
Scilex Holding Company (NASDAQ: SCLX)
NVS vs SCLX Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, SCLX has a market cap of 42.8M. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while SCLX trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas SCLX's P/E ratio is -0.13. In terms of profitability, NVS's ROE is +0.30%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for NVS.Check SCLX's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
NVS vs MIRA Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, MIRA has a market cap of 34.2M. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while MIRA trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas MIRA's P/E ratio is -0.56. In terms of profitability, NVS's ROE is +0.30%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, NVS is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for NVS.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLXW)
NVS vs SCLXW Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, SCLXW has a market cap of 33.6M. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.30%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for NVS.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
NVS vs BDSIW Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, NVS's ROE is +0.30%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVS is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for NVS.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
NVS vs CRXT Comparison September 2026
Novartis AG (NYSE: NVS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 266.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVS is priced at $140.37 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 16.15, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVS's ROE is +0.30%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVS is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for NVS.Check CRXT's competition here